Effects of lithium on lipopolysaccharide-induced inflammation in rat primary glia cells

Innate Immunity

Volumn 18, Issue 3, 2012, Pages 447-458

  Nahman, Sigalit ^a   Belmaker, R H ^a   Azab, Abed N ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Bipolar disorder; cytokines; inflammation; lithium; prostaglandins

Indexed keywords

CYCLOOXYGENASE 2; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; IBUPROFEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LITHIUM; NITRIC OXIDE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIPOLAR DISORDER; CELL ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIA CELL; GRIESS REACTION ASSAY; NERVOUS SYSTEM INFLAMMATION; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIPOLAR DISORDER; CELLS, CULTURED; CYCLOOXYGENASE 2; DINOPROSTONE; DOWN-REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; LITHIUM; NEUROGLIA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PRIMARY CELL CULTURE; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 84861792135     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425911421512     Document Type: Article

References (94)

1. Belmaker RH. Bipolar disorder. N Engl J Med. 2004 ; 351: 476-486
2. Gershon S, Chengappa KN, Malhi GS. Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disord. 2009 ; 11: 34-44
3. Narrow WE, Rae DS, Robins LN. Revised prevalence estimates of mental disorders in the United States: using clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry. 2002 ; 59: 115-123
4. Simon GE, Bauer MS, Ludman EJ, et al. Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. J Clin Psychiatry. 2007 ; 68: 1237-1245
5. Soreca I, Fagiolini A, Frank E, et al. Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder. J Psychiatr Res. 2008 ; 42: 956-961
6. Lenox RH, McNamara RK, Papke RL, et al. Neurobiology of lithium: an update. J Clin Psychiatry. 1998 ; 59: 37-47
7. Goodwin FK. Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. J Clin Psychiatry. 2002 ; 63: 5-12
8. Baethge C, Gruschka P, Berghöfer A, et al. Prophylaxis of schizoaffective disorder with lithium or carbamazepine: outcome after long-term follow-up. J Affect Disord. 2004 ; 79: 43-50
9. Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA. 2005 ; 102: 6990-6995
10. Engel T, Goñi-Oliver P, Gómez de Barreda E, et al. Lithium, a potential protective drug in Alzheimer's disease. Neurodegener Dis. 2008 ; 5: 247-249
11. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res. 2007 ; 32: 577-595
12. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2008 ; 105: 2052-2057
13. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry. 2006 ; 11: 227-240
14. Bowden CL. Making optimal use of combination pharmacotherapy in bipolar disorder. J Clin Psychiatry. 2004 ; 65: 21-24
15. Gitlin M. Lithium and the kidney: an updated review. Drug Saf. 1999 ; 20: 231-243
16. Berridge MJ, Irvine RF. Inositol phosphates and cell signaling. Nature. 1989 ; 341: 197-204
17. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA. 1996 ; 93: 8455-8459
18. Manji HK, Moore GJ, Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked?. Biol. Psychiatry. 1999 ; 46: 929-940
19. Rao JS, Lee HJ, Rapoport SI, et al. Mode of action of mood stabilizers: is the arachidonic acid cascade a common target?. Mol Psychiatry. 2008 ; 13: 585-596
20. Goldstein BI, Kemp DE, Soczynska JK, et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. JClin Psychiatry. 2009 ; 70: 1078-1090
21. Rapoport SI, Basselin M, Kim HW, et al. Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev. 2009 ; 61: 185-209
22. O'Brien SM, Scully P, Scott LV, et al. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 2006 ; 90: 263-267
23. Liu JC, Yang YY, Chou YM, et al. Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol. 2004 ; 150: 116-122
24. Huang TL, Lin FC. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry. 2007 ; 31: 370-372
25. Dickerson F, Stallings C, Origoni A, et al. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007 ; 31: 952-955
26. Begemann M, Sargin D, Rossner MJ, et al. Episode-specific differential gene expression of peripheral blood mononuclear cells in rapid cycling supports novel treatment approaches. Mol Med. 2008 ; 14: 9-10
27. Padmos RC, Hillegers MH, Knijff EM, et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry. 2008 ; 65: 395-407
28. Soczynska JK, Kennedy SH, Goldstein BI, et al. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression?. Neurotoxicology. 2009 ; 30: 497-521
29. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol. 2008 ; 12: 447-458
30. Maes M, Bosmans E, Suy E, et al. Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology. 1990-1991 ; 24: 115-120
31. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011 ; 35: 664-675
32. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry. 1999 ; 4: 317-327
33. Müller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006 ; 11: 680-684
34. Vaccarino V, Brennan ML, Miller AH, et al. Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. Biol Psychiatry. 2008 ; 64: 476-483
35. Gimeno D, Kivimäki M, Brunner EJ, et al. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med. 2009 ; 39: 413-423
36. Dimopoulos N, Piperi C, Psarra V, et al. Increased plasma levels of 8-iso-PGF2alpha and IL-6 in an elderly population with depression. Psychiatry Res. 2008 ; 161: 59-66
37. Manev H, Manev R, Vidovich MI. Depression, inflammation, and cardiovascular disease: is 5-lipoxygenase the missing link?. JAm Coll Cardiol. 2008 ; 51: 1990-1991
38. Milaneschi Y, Corsi AM, Penninx BW, et al. Interleukin-1 receptor antagonist and incident depressive symptoms over 6 years in older persons: the InCHIANTI study. Biol Psychiatry. 2009 ; 65: 973-978
39. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009 ; 71: 171-186
40. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009 ; 65: 732-741
41. Dhabhar FS, Burke HM, Epel ES, et al. Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. J Psychiatr Res. 2009 ; 43: 962-969
42. Müller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002 ; 159: 1029-1034
43. Müller N, Ulmschneider M, Scheppach C, et al. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci. 2004 ; 254: 14-22
44. Haack M, Hinze-Selch D, Fenzel T, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. JPsych Res. 1999 ; 33: 407-418
45. McGeer PL. Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease. Drugs Aging. 2000 ; 17: 1-11
46. Firuzi O, Pratico D. Coxibs and Alzheimer's disease: should they stay or should they go?. Ann Neurol. 2006 ; 59: 219-228
47. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol. 2007 ; 150: 963-976
48. Turrin NP, Rivest S. Innate immune reaction in response to seizures: implications for the neuropathology associated with epilepsy. Neurobiol Dis. 2004 ; 16: 321-334
49. Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol. 2008 ; 23: 87-94
50. Goetzl EJ, An S, Smith WL. Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases. FASEB J. 1995 ; 9: 1051-1058
51. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996 ; 271: 33157-33160
52. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000 ; 69: 145-182
53. Wallace JL. Selective COX-2 inhibitors: is the water becoming muddy?. TiPS. 1999 ; 20: 4-6
54. Coruzzi G, Menozzi A, Dobrilla G. Novel non-steroidal anti-inflammatory drugs: what we have learned from animal studies. Curr Drugs Targets Inflamm Allergy. 2004 ; 3: 43-61
55. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999 ; 96: 272-277
56. Merrill JE, Murphy SP, Mitrovic B, et al. Inducible nitric oxide synthase and nitric oxide production by oligodendrocytes. JNeurosci Res. 1997 ; 48: 372-384
57. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J. 1994 ; 298: 249-258
58. Moncada S, Bolanos JP. Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem. 2006 ; 97: 1676-1689
59. Selek S, Savas HA, Gergerlioglu HS, et al. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord. 2008 ; 107: 89-94
60. Savas HA, Gergerlioglu HS, Armutcu F, et al. Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J Biol Psychiatry. 2006 ; 1: 51-55
61. Bosetti F, Rintala J, Seemann R, et al. Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E2 concentration in rat brain. Mol Psychiatry. 2002 ; 7: 845-850
62. Chang MC, Contreras MA, Rosenberger TA, et al. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J Neurochem. 2001 ; 77: 796-803
63. Bazinet RP, Rao JS, Chang L, et al. Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorder. Biol Psychiatry. 2006 ; 59: 401-407
64. Lee HJ, Ertley RN, Rapoport SI, et al. Chronic administration of lamotrigine downregulates COX-2 mRNA and protein in rat frontal cortex. Neurochem Res. 2008 ; 33: 861-866
65. Guo JY, Li CY, Ruan YP, et al. Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol. 2009 ; 612: 54-60
66. Castanon N, Leonard BE, Neveu PJ, et al. Effects of antidepressants on cytokine production and actions. Brain Behav Immun. 2002 ; 16: 569-574
67. Lim CM, Kim SW, Park JY, et al. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res. 2009 ; 87: 1037-1045
68. Rao R, Hao CM, Breyer MD. Hypertonic stress activates glycogen synthase kinase 3beta-mediated apoptosis of renal medullary interstitial cells, suppressing an NFkappaB-driven cyclooxygenase-2-dependent survival pathway. J Biol Chem. 2004 ; 279: 3949-3955
69. Haertel-Wiesmann M, Liang Y, Fantl WJ, et al. Regulation of cyclooxygenase-2 and periostin by Wnt-3 in mouse mammary epithelial cells. J Biol Chem. 2000 ; 275: 32046-32051
70. Kotnik P, Nielsen J, Kwon TH, et al. Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 ; 288: F1053 - F1068
71. Aschner M. Immune and inflammatory responses in the CNS: modulation by astrocytes. Toxicol Lett. 1998 ; 102-103: 283-287
72. Allen NJ, Barres BA. Glia-more than just brain glue. Nature. 2009 ; 457: 675-677
73. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996 ; 19: 312-318
74. Shemi D, Azab AN, Kaplanski J. Time-dependent effect of LPS on PGE2 and TNF-α production by ray glial brain culture: influence of COX and cytokine inhibitors. J Endotoxin Res. 2001 ; 6: 377-381
75. Tenenbaum M, Azab AN, Kaplanski J. Effect of estrogen against LPS-induced inflammation and toxicity in primary rat glial and neuronal cultures. J Endotoxin Res. 2007 ; 13: 158-166
76. Green LC, Wagner DA, Glogowski J, et al. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem. 1982 ; 126: 131-138
77. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 ; 72: 248-254
78. Beurel E, Jope RS. Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain. J Neuroinflammation. 2009 ; 6: 9-9
79. Yuskaitis CJ, Jope RS. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal. 2009 ; 21: 264-273
80. Martin M, Rehani K, Jope RS, et al. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol. 2005 ; 6: 777-784
81. Ichiyama T, Okada K, Lipton JM, et al. Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB. Brain Res. 2000 ; 857: 246-251
82. Rao JS, Bazinet RP, Rapoport SI, et al. Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-kappaB DNA binding activity and COX-2 mRNA. Bipolar Disord. 2007 ; 9: 513-520
83. Peng GS, Li G, Tzeng NS, et al. Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Mol Brain Res. 2005 ; 134: 162-169
84. Chen PS, Wang CC, Bortner CD, et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience. 2007 ; 149: 203-212
85. Jope RS. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci. 2003 ; 24: 441-443
86. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 1996 ; 6: 1664-1668
87. Hoeflich KP, Luo J, Rubie EA, et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 2000 ; 406: 26-27
88. Whittle BJ, Varga C, Pósa A, et al. Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta. Br J Pharmacol. 2006 ; 147: 575-582
89. Cuzzocrea S, Crisafulli C, Mazzon E, et al. Inhibition of glycogen synthase kinase-3beta attenuates the development of carrageenan-induced lung injury in mice. Br J Pharmacol. 2006 ; 149: 687-702
90. Cuzzocrea S, Mazzon E, Di Paola R, et al. Glycogen synthase kinase-3beta inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. Clin Immunol. 2006 ; 120: 57-67
91. Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun. 2007 ; 21: 374-383
92. Shintani F, Kanba S, Nakaki T, et al. Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J Neurosci. 1993 ; 13: 3574-3581
93. Guloksuz S, Cetin EA, Cetin T, et al. Cytokine levels in euthymic bipolar patients. J Affect Disord. 2010 ; 126: 458-462
94. Himmerich H, Koethe D, Schuld A, et al. Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. Psychopharmacology. 2005 ; 179: 447-451